Stoke Therapeutics receives authorization to initiate STK-002 study in UK

Stoke Therapeutics announced authorization of its clinical trial application, or CTA, by the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, to initiate a Phase 1/2 study of STK-002 for the treatment of autosomal dominant optic atrophy, or ADOA, the most common inherited optic nerve disorder.